Kenneth Blum^1-7* and Rajendra D Badgaiyan^8,9

¹Department of Nutrigenomics, Geneus Health, LLC, San Antonio, TX, USA
²Department of Psychiatry, University of Vermont, Burlington, VT, USA
³Western University Health Science Centers, Graduate College, Pompano, CA, USA
⁴Institute of Psychology, Eotvos Loránd University, Budapest, Hungary
⁵Department of Psychiatry, Wright University Boonshoft School of Medicine, Dayton, OH, USA
⁶The Kenneth Blum Behavioral and Neurogenetic Institute, (Division of Ivitalize Inc), Austin, TX, USA
⁷Division of Nutrigenomics, Victory Nutrition International, LLC, Lederoch, PA, USA
⁸Department of Psychiatry, South Texas Veteran Health Care System, Audie L. Murphy Memorial VA Hospital and Long School of Medicine, University of Texas Health Science Center, San Antonio, TX, USA
⁹Department of Psychiatry, MT. Sinai School of Medicine, New York, NY., USA

*Corresponding Author: Kenneth Blum, Department of Nutrigenomics, Geneus Health, LLC, San Antonio, TX, USA.

Received: July 28, 2021; Published: August 19, 2021

  Currently planet earth is in deep trouble housing not only the Covid pandemic with new strains like delta and epsilon and many people not willing to get vaccinated thereby spreading the virus globally, but our drug and non-drug addiction pandemic as well. Nora Volkow director of the National Institute on Drug Abuse (NIDA) estimated that opioid induced overdoses increased to 30 - 40 percent post COVID. In fact, in 2020, 93,000 people died from narcotic overdoses. In the face of the current Opioid crisis in America killing close to 1,000,000 people since 2004, and even more when we consider tobacco smoking, we are hereby proposing a novel approach to assist in at least attenuating these unwanted premature deaths. The current approach is failing, and other alternative approaches should at least be tested [1].

References

1. Hall SM., et al. “Cigarette Smoking Cessation Intervention for Buprenorphine Treatment Patients”. Nicotine and Tobacco Research5 (2018): 628-635.
2. Casey BJ., et al. “DSM-5 and RDoC: progress in psychiatry research?” Nature Reviews on Neuroscience11 (2013): 810-814.
3. Herz A. “Multiple opiate receptors and their functional significance”. Journal of Neural Transmission 18 (1983): 227-233.
4. Blum K., et al. “Isoquinoline alkaloids as possible regulators of alcohol addiction”. Lancet 8015 (1977): 799-800.
5. Downs BW., et al. “Death by Opioids: Are there non-addictive scientific solutions?” Journal of Systems and Integrative Neuroscience (JSIN) 5 (2019).
6. Detrick JA., et al. “Motor cortex modulation and reward in children with attention-deficit/hyperactivity disorder”. Brain Communication2 (2021): fcab093.
7. Swenson S., et al. “The therapeutic potential of exercise for neuropsychiatric diseases: A review”. Journal of the Neurological Sciences 412 (2020): 116763.
8. Olsen RW. “GABAA receptor: Positive and negative allosteric modulators”. Neuropharmacology 136 (2018): 10-22.
9. Gondré-Lewis MC., et al. “Pre-clinical models of reward deficiency syndrome: A behavioral octopus”. Neuroscience and Biobehavioral Reviews 115 (2020): 164-188.
10. Blum K., et al. “Biotechnical development of genetic addiction risk score (GARS) and selective evidence for inclusion of polymorphic allelic risk in substance use disorder (SUD)”. Journal of Systems and Integrative Neuroscience2 (2020): 10.
11. McLaughlin T., et al. “Pro-dopamine regulator, KB220Z, attenuates hoarding and shopping behavior in a female, diagnosed with SUD and ADHD”. Journal of Behavioral Addictions 1 (2018): 192-203.
12. Blum K., et al. “Pro-Dopamine Regulator (KB220) A Fifty Year Sojourn to Combat Reward Deficiency Syndrome (RDS): Evidence Based Bibliography (Annotated)”. CPQ Neurology and Psychology 2 (2018).
13. Blum K., et al. “Overcoming qEEG abnormalities and reward gene deficits during protracted abstinence in male psychostimulant and polydrug abusers utilizing putative dopamine D₂ agonist therapy: part 2”. Postgraduate Medicine6 (2010): 214-226.
14. Blum K., et al. “rsfMRI effects of KB220Z™ on neural pathways in reward circuitry of abstinent genotyped heroin addicts”. Postgraduate Medicine2 (2015): 232-241.
15. Blum K., et al. “A Novel Precision Approach to Overcome the "Addiction Pandemic" by Incorporating Genetic Addiction Risk Severity (GARS) and Dopamine Homeostasis Restoration”. Journal of Personalized Medicine 3 (2021): 212.
16. Fried L., et al. “Hypodopaminergia and "Precision Behavioral Management" (PBM): It is a Generational Family Affair”. Current Pharmaceutical Biotechnology 6 (2020): 528-541.
17. Febo M., et al. “Enhanced functional connectivity and volume between cognitive and reward centers of naïve rodent brain produced by pro-dopaminergic agent KB220Z”. PLoS One4 (2017): e0174774.
18. Badgaiyan RD., et al. “Attenuated Tonic and Enhanced Phasic Release of Dopamine in Attention Deficit Hyperactivity Disorder”. PLoS One 9 (2015): e0137326.
19. Abijo T., et al. “Neuropharmacological and Neurogenetic Correlates of Opioid Use Disorder (OUD) As a Function of Ethnicity: Relevance to Precision Addiction Medicine”. Current Neuropharmacology 7 (2020): 578-595.

Citation

Citation: Kenneth Blum and Rajendra D Badgaiyan. “Can We Change the Current Landscape of All Addictive Behaviors by Adopting a Personalized Genetic Guided Approach to Help Epigenetically Induce Dopamine Homeostasis at the Brain Reward Circuit?". Acta Scientific Neurology 4.9 (2021): 46-48.

Copyright

Copyright: © 2021 Kenneth Blum and Rajendra D Badgaiyan. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.